{"id":"NCT00432679","sponsor":"GlaxoSmithKline","briefTitle":"A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study","officialTitle":"Clinical Evaluation of Rosiglitazone Maleate (BRL49653C) in Patients With Type 2 Diabetes Mellitus (Combination Therapy With Sulfonyl Urea) - A Placebo-Controlled Double-Blind Study -","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-05-24","primaryCompletion":"2007-03-28","completion":"2007-03-28","firstPosted":"2007-02-08","resultsPosted":"2019-02-08","lastUpdate":"2022-12-12"},"enrollment":149,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Rosiglitazone (BRL49653C)","otherNames":[]}],"arms":[{"label":"arm 1","type":"EXPERIMENTAL"}],"summary":"This study was designed to compare the efficacy and safety of BRL49653C versus placebo with concomitant use of sulfonyl urea (SU).","primaryOutcome":{"measure":"Change From Baseline in Glycosylated Hemoglobin (HbA1c) After 16 Weeks of Treatment in Rosiglitazone Group and Placebo Group","timeFrame":"Baseline (Day 0) and Week 16","effectByArm":[{"arm":"Rosiglitazone 4 mg Orally Once Daily","deltaMin":-0.62,"sd":0.074},{"arm":"Placebo","deltaMin":0.19,"sd":0.073}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":4,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":74},"commonTop":["Nasopharyngitis","Upper respiratory tract inflammation","Blood creatine phosphokinase increased","Weight increased","Blood triglyccrides increased"]}}